Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
ULORIC
Generic name / active ingredient
febuxostat
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-25

Copy from the pack in hand

Source-linked reading points

  • Check ULORIC, febuxostat, 40 mg or 80 mg, the actual NDC, 30-tablet bottle, oral-tablet form and target market together. Seeing only “febuxostat” or one mg number does not prove that another strength, package, brand or market product is the same.
  • The 40 mg, 80 mg and “30-tablet bottle” wording identifies two exact label panels; it does not say how many tablets to use, when to adjust, whether to make up a missed use or whether another pack can be self-switched. Take the current pack, prescription and full medicine list to a pharmacist or prescribing team for any real-use question.
  • The current label contains a boxed warning about cardiovascular death and places cardiovascular history and the complete medicine list within professional review. This warning is a reading and help-seeking cue; it does not let a webpage decide whether an individual should continue, start, stop or change any urate-lowering product.
  • The label lists contraindications with azathioprine or mercaptopurine; a pharmacist or clinician should also review every prescription medicine, OTC product, supplement, prior reaction and the exact product. Do not self-add, stop, switch, separate or make up any medicine because an interaction or warning appears on a webpage.

Reviewed presentation examples — compare every field

  • 40 mg per tablet; 30-tablet bottleNDC 64764-918-30
  • 80 mg per tablet; 30-tablet bottleNDC 64764-677-30

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-25
Source record
1 clickable primary-source entry point is listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image